Twenty-one patients with multiple myeloma were treated with idarubicin 45 mg/m2 orally day 1 and prednisone 60 mg/m2 day 1-4 every three weeks. Moderate to severe gastrointestinal and hematopoietic toxicity were observed. Twelve of the twenty-one patients had relapsed on prior treatment. Of these, 2 patients responded. Two patients had primary resistant disease, neither responded. Seven patients had no prior treatment, three responded. ldarubicin and prednisone have modest activity in refractory myeloma, with short duration of response and severe toxicity.
Get full access to this article
View all access options for this article.
References
1.
BergsagelD.E., RiderW.D.: Plasma cell neoplasms. In: Cancer Principles and Practice of Oncology.De VitaV.T., HellmanS., RosenbergS.A. (Eds). 1753–1795. J.B. Lippincott Company, New York1985.
2.
ChisesiT., CapnistG., De DominicisE., DiniE.: A Phase II study of Idarubicin (4-demethoxydaunorubicin) in advanced myeloma. Eur. J. Cancer Clin. Oncol., 24: 681–684, 1988.
3.
DurieB.G.M., SalmonS.E.: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer, 36: 842–854, 1975.
4.
Lambertenghi-DeliliersG., PaglianiE., MaioloA.T., Paccia-riniM.A., PolliE.E.: Therapeutic activity of 4-demethoxydaunorubicin (Idarubicin) in adult acute leukemia. Tumori, 69: 515–519, 1983.
5.
LopezM., LazzaroB., Di LanzoL., PapaldoP., GanginaF., Di PietroN.: Activity of oral 4-demethoxydaunorubicin in non-Hodgkin's lymphoma. 14th International Congress of Chemotherapy, Kyato, Japan, 39: WS410, 1985.
6.
OkenM.M., CreechR.H., TormeyD.C., HortonJ., DavisT.E., McFaddenE.T., CarboneP.P.: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncology (CCT), 5: 649–655, 1982.
